Gabapentin encarbil (Horizant) for restless leg syndrome.

Abstract

Gabapentin enacarbil (Horizant-GlaxoSmithKline), a new extended-release (ER) tablet formulation of gabapentin, has been approved by the FDA for treatment of moderate-to-severe restless legs syndrome (RLS). The immediate-release (IR) formulation of gabapentin (Neurontin,and others), which is approved for treatment of epilepsy and postherpetic neuralgia, has been used for many years to treat RLS. Another ER tablet formulation of gabapentin (Gralise) has been approved by the FDA for treatment of postherpetic neuralgia.

• Journal: The Medical letter on drugs and therapeutics (Med Lett Drugs Ther) Vol. 53 Issue 1372 Pg. 70-1 (Sep 05 2011) ISSN: 1523-2859 [Electronic] United States
• PMID: 21897349 (Publication Type: Journal Article)
• Copyright: © 2011 The Medical Letter, Inc.

Chemical References

• 1-(((alpha-isobutanoyloxyethoxy)carbonyl)aminomethyl)-1-cyclohexaneacetic acid
• Carbamates
• Delayed-Action Preparations
• gamma-Aminobutyric Acid

Topics

• Carbamates (administration & dosage, adverse effects, therapeutic use)
• Delayed-Action Preparations
• Humans
• Restless Legs Syndrome (drug therapy)
• gamma-Aminobutyric Acid (administration & dosage, adverse effects, analogs & derivatives, therapeutic use)